Eddy Anglade, MD
Chief Medical Officer, Lux Biosciences, Inc.
2
0
0
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (2)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Edward J Holland, MD
University of Cincinnati and Cincinnati Eye Institute
Shared therapeutic areas:
Jon Dishler, M. D.
Dishler Laser Institute
Shared therapeutic areas:
Ahmed A Tabl, MD
Benha University
Shared therapeutic areas:
Dennis Burger, O. D.
Kaiser Permanente, Oakland
Shared therapeutic areas:
Cynthia A Toth, MD
Duke University
Shared therapeutic areas:
Mark J Mannis, MD
University of California, Davis
Shared therapeutic areas:
Priya M Mathews, MD
Keratoplasty Alliance International
Shared therapeutic areas:
Vincent Daien, MD, PhD, HDR
University Hospitals of Montpellier
Shared therapeutic areas:
Evangelos Terpos, Prof
Department of Clinical Therapeutics, School of Medicine, National Kapodistrian University of Athens (NKUA)
Shared therapeutic areas:
Winston Chamberlain, MD, PhD
Oregon Health and Science University
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (2)
Showing 2 of 2 trials
Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk
Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty
All 2 trials loaded